Bettinger JA, Liberator P, Halperin SA, et al. - Given that invasive meningococcal disease induced by Neisseria meningitidis serogroup B (MenB) continue to pose a health risk in Canada and globally, and two MenB vaccines are now approved for use, and since there is a necessity for acquiring an understanding of the genotype of Canadian strains and the potential strain coverage conferred by the MenB-FHbp (factor H binding protein) vaccine in order to notify immunization policies, so, researchers undertook this study addressing this topic. As a component of the Canadian Immunization Monitoring Program Active surveillance network, serogroup B Neisseria meningitidis strains liable for meningococcal disease in Canada from 2006 to 2012 were obtained. Genotypic analysis was performed on MenB isolates from 2006 to 2012, with ascertainment of fHbp surface expression for a subset of isolates: those happening from 2010 to 2012. Findings revealed that the expression of fHbp seen on the majority of MenB isolates accountable for meningococcal disease in Canada was at levels predicted to be sufficient for complement mediated bactericidal activity in the presence of MenB-FHbp induced serum antibodies.